Table 2.
Univariate and multivariate analysis of biochemical failure and distant metastasis in the LDR‐PB cohort
| Variables | Biochemical failure | Distant metastasis | ||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||
| P | P | HR | P | P | HR | |
| Pretreatment PSA (≤10 vs >10 ng/mL) | 0.171 | 0.351 | 1.589 | 0.029 | 0.283 | 1.969 |
| Gleason score (4–6 vs. 7–10) | 0.001 | 0.001 | 5.526 | 0.015 | 0.028 | 4.502 |
| T‐stage (T1c–T2a vs. T2b–T3) | 0.889 | 0.573 | ||||
| Total BED (≤210 vs. >210 Gy2) | 0.303 | 0.038 | 0.133 | 3.523 | ||
| nPSA12 (≤0.7 vs. >0.7 ng/mL) | 0.004 | 0.004 | 6.191 | 0.010 | 0.020 | 11.508 |
LDR‐PB, low‐dose‐rate prostate brachytherapy; PSA, prostate‐specific antigen; BED, biologically effective dose; nPSA12, prostate‐specific antigen nadir within 12 months; HR, hazard ratio. Boldface P values are statistically significant (< 0.05).